Kauffman Michael
SEC-identified person · CIK 1364719 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Kyntra BIO, INC. KYNB | Director | filed 2025 - 2026 |
| Kezar Life Sciences, Inc. KZR | Director | filed 2018 - 2026 |
| Verastem, Inc. VSTM | Director · President of Development | filed 2012 - 2026 |
| Restorbio, Inc. TORC | Director | filed 2021 - 2024 |
| Karyopharm Therapeutics Inc. KPTI | Director · President, CEO & CMO | filed 2013 - 2022 |
| Infinity Pharmaceuticals, INC. INFI | Director | filed 2017 - 2019 |
| Zalicus Inc. ZLCS | Director | filed 2006 - 2013 |
| Onyx Pharmaceuticals INC ONXX | Chief Medical Officer | filed 2009 - 2010 |
| Bioenvision INC BIVN | Director | filed 2006 - 2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.